EP3630944A1 - Method of generation bacterial compositions comprising a biofilm with benefecial bacteria - Google Patents
Method of generation bacterial compositions comprising a biofilm with benefecial bacteriaInfo
- Publication number
- EP3630944A1 EP3630944A1 EP18810460.8A EP18810460A EP3630944A1 EP 3630944 A1 EP3630944 A1 EP 3630944A1 EP 18810460 A EP18810460 A EP 18810460A EP 3630944 A1 EP3630944 A1 EP 3630944A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- biofilm
- bacteria
- medium
- species
- subtilis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 281
- 239000000203 mixture Substances 0.000 title claims abstract description 134
- 238000000034 method Methods 0.000 title claims abstract description 94
- 230000001580 bacterial effect Effects 0.000 title claims abstract description 88
- 230000009286 beneficial effect Effects 0.000 claims abstract description 119
- 230000012010 growth Effects 0.000 claims abstract description 80
- 239000000758 substrate Substances 0.000 claims abstract description 33
- 238000012258 culturing Methods 0.000 claims abstract description 32
- 238000000338 in vitro Methods 0.000 claims abstract description 9
- 244000052616 bacterial pathogen Species 0.000 claims abstract description 6
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 113
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 93
- 239000002609 medium Substances 0.000 claims description 77
- ROWKJAVDOGWPAT-UHFFFAOYSA-N Acetoin Chemical compound CC(O)C(C)=O ROWKJAVDOGWPAT-UHFFFAOYSA-N 0.000 claims description 72
- 241000894007 species Species 0.000 claims description 62
- 239000006041 probiotic Substances 0.000 claims description 55
- 235000018291 probiotics Nutrition 0.000 claims description 55
- 230000000529 probiotic effect Effects 0.000 claims description 51
- GFAZHVHNLUBROE-UHFFFAOYSA-N hydroxymethyl propionaldehyde Natural products CCC(=O)CO GFAZHVHNLUBROE-UHFFFAOYSA-N 0.000 claims description 36
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 31
- 235000013305 food Nutrition 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 239000001963 growth medium Substances 0.000 claims description 15
- 235000013336 milk Nutrition 0.000 claims description 12
- 239000008267 milk Substances 0.000 claims description 12
- 210000004080 milk Anatomy 0.000 claims description 12
- 239000008121 dextrose Substances 0.000 claims description 11
- 230000036541 health Effects 0.000 claims description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 10
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- 241001112724 Lactobacillales Species 0.000 claims description 7
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052748 manganese Inorganic materials 0.000 claims description 6
- 239000011572 manganese Substances 0.000 claims description 6
- 230000037361 pathway Effects 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 description 89
- 229920001817 Agar Polymers 0.000 description 62
- 235000010419 agar Nutrition 0.000 description 59
- 239000008272 agar Substances 0.000 description 58
- 238000003501 co-culture Methods 0.000 description 52
- 230000032770 biofilm formation Effects 0.000 description 33
- 239000000047 product Substances 0.000 description 32
- 238000004519 manufacturing process Methods 0.000 description 30
- 230000004083 survival effect Effects 0.000 description 30
- 229940041514 candida albicans extract Drugs 0.000 description 23
- 239000012138 yeast extract Substances 0.000 description 21
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 20
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 20
- 210000002744 extracellular matrix Anatomy 0.000 description 20
- 239000000463 material Substances 0.000 description 20
- 239000011159 matrix material Substances 0.000 description 20
- 230000014509 gene expression Effects 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- 239000006872 mrs medium Substances 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 16
- 241000282414 Homo sapiens Species 0.000 description 15
- 238000009472 formulation Methods 0.000 description 15
- 244000005700 microbiome Species 0.000 description 15
- 229960005486 vaccine Drugs 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- 230000001413 cellular effect Effects 0.000 description 12
- 230000029087 digestion Effects 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 241000186660 Lactobacillus Species 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 241000196324 Embryophyta Species 0.000 description 10
- 229920002444 Exopolysaccharide Polymers 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 230000009977 dual effect Effects 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 229940039696 lactobacillus Drugs 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000000306 component Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 229910052500 inorganic mineral Inorganic materials 0.000 description 9
- 230000000968 intestinal effect Effects 0.000 description 9
- 235000010755 mineral Nutrition 0.000 description 9
- 239000011707 mineral Substances 0.000 description 9
- 238000009343 monoculture Methods 0.000 description 9
- 241000194108 Bacillus licheniformis Species 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000003623 enhancer Substances 0.000 description 8
- 239000000835 fiber Substances 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 235000015097 nutrients Nutrition 0.000 description 8
- 244000063299 Bacillus subtilis Species 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- -1 Mn2+ ions Chemical class 0.000 description 7
- 229910002651 NO3 Inorganic materials 0.000 description 7
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 7
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 239000004310 lactic acid Substances 0.000 description 7
- 235000014655 lactic acid Nutrition 0.000 description 7
- 235000012054 meals Nutrition 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 230000007704 transition Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 230000035899 viability Effects 0.000 description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
- 239000001888 Peptone Substances 0.000 description 6
- 108010080698 Peptones Proteins 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 235000014106 fortified food Nutrition 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019319 peptone Nutrition 0.000 description 6
- 229960004793 sucrose Drugs 0.000 description 6
- 235000015193 tomato juice Nutrition 0.000 description 6
- 239000012137 tryptone Substances 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 5
- 241000186000 Bifidobacterium Species 0.000 description 5
- 241000192700 Cyanobacteria Species 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 241000606790 Haemophilus Species 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 230000001332 colony forming effect Effects 0.000 description 5
- 235000013365 dairy product Nutrition 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000000644 propagated effect Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 238000012876 topography Methods 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- 241000187844 Actinoplanes Species 0.000 description 4
- 241001322378 Bacillus paralicheniformis Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000206672 Gelidium Species 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000006137 Luria-Bertani broth Substances 0.000 description 4
- 108090000099 Neurotrophin-4 Proteins 0.000 description 4
- 102100038567 Properdin Human genes 0.000 description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000005862 Whey Substances 0.000 description 4
- 108010046377 Whey Proteins Proteins 0.000 description 4
- 102000007544 Whey Proteins Human genes 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 235000013681 dietary sucrose Nutrition 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 239000003337 fertilizer Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229960001375 lactose Drugs 0.000 description 4
- 235000021486 meal replacement product Nutrition 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 150000003956 methylamines Chemical class 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 102000003390 tumor necrosis factor Human genes 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000187362 Actinomadura Species 0.000 description 3
- 241001147780 Alicyclobacillus Species 0.000 description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 108010060123 Conjugate Vaccines Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 241000192091 Deinococcus radiodurans Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 108010072039 Histidine kinase Proteins 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 3
- 241000605121 Nitrosomonas europaea Species 0.000 description 3
- 241000202223 Oenococcus Species 0.000 description 3
- 244000203593 Piper nigrum Species 0.000 description 3
- 235000008184 Piper nigrum Nutrition 0.000 description 3
- 241000186429 Propionibacterium Species 0.000 description 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 3
- 208000037386 Typhoid Diseases 0.000 description 3
- 229960000458 allantoin Drugs 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000004927 clay Substances 0.000 description 3
- 229940031670 conjugate vaccine Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000002917 insecticide Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000009928 pasteurization Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 description 3
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 description 3
- 230000008635 plant growth Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000004626 scanning electron microscopy Methods 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229960000814 tetanus toxoid Drugs 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 201000008297 typhoid fever Diseases 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- ALRHLSYJTWAHJZ-UHFFFAOYSA-N 3-hydroxypropionic acid Chemical compound OCCC(O)=O ALRHLSYJTWAHJZ-UHFFFAOYSA-N 0.000 description 2
- 239000006663 5% sorbitol medium Substances 0.000 description 2
- 241000201860 Abiotrophia Species 0.000 description 2
- 241000589220 Acetobacter Species 0.000 description 2
- 241000589158 Agrobacterium Species 0.000 description 2
- 241000611270 Alcanivorax borkumensis Species 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108010024976 Asparaginase Proteins 0.000 description 2
- 102000015790 Asparaginase Human genes 0.000 description 2
- 244000075850 Avena orientalis Species 0.000 description 2
- 235000007319 Avena orientalis Nutrition 0.000 description 2
- 241000194107 Bacillus megaterium Species 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 241001134770 Bifidobacterium animalis Species 0.000 description 2
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 241000186012 Bifidobacterium breve Species 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 241000193764 Brevibacillus brevis Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 241001489099 Cantharellus Species 0.000 description 2
- 235000002566 Capsicum Nutrition 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 240000000467 Carum carvi Species 0.000 description 2
- 235000005747 Carum carvi Nutrition 0.000 description 2
- 241000863012 Caulobacter Species 0.000 description 2
- 240000001817 Cereus hexagonus Species 0.000 description 2
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical compound [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241001422920 Dechloromonas aromatica Species 0.000 description 2
- 241001465321 Eremothecium Species 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 2
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 241000205062 Halobacterium Species 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000003996 Interferon-beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102100039898 Interleukin-18 Human genes 0.000 description 2
- 241001647418 Lactobacillus paralimentarius Species 0.000 description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 241001512042 Methylibium petroleiphilum Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 102000004230 Neurotrophin 3 Human genes 0.000 description 2
- 108090000742 Neurotrophin 3 Proteins 0.000 description 2
- 102000003683 Neurotrophin-4 Human genes 0.000 description 2
- 102100033857 Neurotrophin-4 Human genes 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 241000589597 Paracoccus denitrificans Species 0.000 description 2
- 239000006002 Pepper Substances 0.000 description 2
- 235000016761 Piper aduncum Nutrition 0.000 description 2
- 235000017804 Piper guineense Nutrition 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 101800004937 Protein C Proteins 0.000 description 2
- 102000017975 Protein C Human genes 0.000 description 2
- 241000589776 Pseudomonas putida Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 101800001700 Saposin-D Proteins 0.000 description 2
- 108010086019 Secretin Proteins 0.000 description 2
- 102100037505 Secretin Human genes 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 241001659629 Virgibacillus Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 108010056760 agalsidase beta Proteins 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000006674 alicyclobacillus medium Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 229940118852 bifidobacterium animalis Drugs 0.000 description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 2
- 229940004120 bifidobacterium infantis Drugs 0.000 description 2
- 229940009289 bifidobacterium lactis Drugs 0.000 description 2
- 229940009291 bifidobacterium longum Drugs 0.000 description 2
- 239000007624 bifidobacterium medium Substances 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 239000002551 biofuel Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000007371 caulobacter medium Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000006782 corynebacterium agar Substances 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 235000011950 custard Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 description 2
- 108010067396 dornase alfa Proteins 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 244000000021 enteric pathogen Species 0.000 description 2
- 239000003344 environmental pollutant Substances 0.000 description 2
- 230000006353 environmental stress Effects 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 238000012851 eutrophication Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000000446 fuel Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 239000006481 glucose medium Substances 0.000 description 2
- 235000011868 grain product Nutrition 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000006519 halobacteria medium Substances 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 230000002363 herbicidal effect Effects 0.000 description 2
- 239000004009 herbicide Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 229960001388 interferon-beta Drugs 0.000 description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000006327 marine agar Substances 0.000 description 2
- 239000006325 marine broth Substances 0.000 description 2
- 229940035102 meningococcal group b vaccine Drugs 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000007003 mineral medium Substances 0.000 description 2
- 239000006870 ms-medium Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000005645 nematicide Substances 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 229940032018 neurotrophin 3 Drugs 0.000 description 2
- 229940097998 neurotrophin 4 Drugs 0.000 description 2
- 239000006916 nutrient agar Substances 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- 108010001564 pegaspargase Proteins 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229940075559 piperine Drugs 0.000 description 2
- 235000019100 piperine Nutrition 0.000 description 2
- 239000005648 plant growth regulator Substances 0.000 description 2
- 231100000719 pollutant Toxicity 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 229960000856 protein c Drugs 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000003128 rodenticide Substances 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 229960002101 secretin Drugs 0.000 description 2
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 244000000000 soil microbiome Species 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000007077 tomato juice medium Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 108010050327 trypticase-soy broth Proteins 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 235000015192 vegetable juice Nutrition 0.000 description 2
- 229940104152 vivotif Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 239000007206 ypm medium Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 229940124962 ActHIB Drugs 0.000 description 1
- 241000193798 Aerococcus Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000609240 Ambelania acida Species 0.000 description 1
- 241001147782 Amphibacillus Species 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000555286 Aneurinibacillus Species 0.000 description 1
- 241001626813 Anoxybacillus Species 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000193836 Atopobium rimae Species 0.000 description 1
- 241000589151 Azotobacter Species 0.000 description 1
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 1
- 241000193752 Bacillus circulans Species 0.000 description 1
- 241001328122 Bacillus clausii Species 0.000 description 1
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 241000006382 Bacillus halodurans Species 0.000 description 1
- 241000193422 Bacillus lentus Species 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 229940124899 Biothrax Drugs 0.000 description 1
- 241000555281 Brevibacillus Species 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 102100031092 C-C motif chemokine 3 Human genes 0.000 description 1
- 101710155856 C-C motif chemokine 3 Proteins 0.000 description 1
- 102100031102 C-C motif chemokine 4 Human genes 0.000 description 1
- 101710155855 C-C motif chemokine 4 Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000206594 Carnobacterium Species 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241001660259 Cereus <cactus> Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 241001135744 Colwellia Species 0.000 description 1
- 240000006766 Cornus mas Species 0.000 description 1
- 235000003363 Cornus mas Nutrition 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 241001430190 Eggerthia catenaformis Species 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 108010075944 Erythropoietin Receptors Proteins 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 241000321606 Filobacillus Species 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241001261512 Gracilibacillus Species 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108700035897 Haemophilus influenzae HibTITER Proteins 0.000 description 1
- 108010050195 Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine Proteins 0.000 description 1
- 241000193004 Halobacillus Species 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108700037566 Hib-MenCY-TT vaccine Proteins 0.000 description 1
- 229940124885 Hiberix Drugs 0.000 description 1
- 108700020122 Hiberix Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 241000193404 Hydrogenibacillus schlegelii Species 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241000186778 Kandleria vitulina Species 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 241000186717 Lactobacillus acetotolerans Species 0.000 description 1
- 241000110061 Lactobacillus acidifarinae Species 0.000 description 1
- 241000028630 Lactobacillus acidipiscis Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 241000186716 Lactobacillus agilis Species 0.000 description 1
- 241001507052 Lactobacillus algidus Species 0.000 description 1
- 241000186715 Lactobacillus alimentarius Species 0.000 description 1
- 241001647783 Lactobacillus amylolyticus Species 0.000 description 1
- 241000186714 Lactobacillus amylophilus Species 0.000 description 1
- 241000168643 Lactobacillus amylotrophicus Species 0.000 description 1
- 241000186713 Lactobacillus amylovorus Species 0.000 description 1
- 241000186712 Lactobacillus animalis Species 0.000 description 1
- 241000316282 Lactobacillus antri Species 0.000 description 1
- 241000954248 Lactobacillus apodemi Species 0.000 description 1
- 241000186711 Lactobacillus aviarius Species 0.000 description 1
- 241000186723 Lactobacillus bifermentans Species 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 241000186679 Lactobacillus buchneri Species 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 241000489238 Lactobacillus camelliae Species 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 241000902616 Lactobacillus ceti Species 0.000 description 1
- 241001061980 Lactobacillus coleohominis Species 0.000 description 1
- 241001468197 Lactobacillus collinoides Species 0.000 description 1
- 241000933456 Lactobacillus composti Species 0.000 description 1
- 241000838743 Lactobacillus concavus Species 0.000 description 1
- 241000186842 Lactobacillus coryniformis Species 0.000 description 1
- 241000218492 Lactobacillus crispatus Species 0.000 description 1
- 241000861211 Lactobacillus crustorum Species 0.000 description 1
- 241001134659 Lactobacillus curvatus Species 0.000 description 1
- 241001647786 Lactobacillus delbrueckii subsp. delbrueckii Species 0.000 description 1
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 1
- 241000500356 Lactobacillus dextrinicus Species 0.000 description 1
- 241000790171 Lactobacillus diolivorans Species 0.000 description 1
- 241000976279 Lactobacillus equi Species 0.000 description 1
- 241001026944 Lactobacillus equigenerosi Species 0.000 description 1
- 241000186841 Lactobacillus farciminis Species 0.000 description 1
- 241000831741 Lactobacillus farraginis Species 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000015236 Lactobacillus fornicalis Species 0.000 description 1
- 241000186839 Lactobacillus fructivorans Species 0.000 description 1
- 241001493843 Lactobacillus frumenti Species 0.000 description 1
- 241000370757 Lactobacillus fuchuensis Species 0.000 description 1
- 241000509544 Lactobacillus gallinarum Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 241000316283 Lactobacillus gastricus Species 0.000 description 1
- 241000950383 Lactobacillus ghanensis Species 0.000 description 1
- 241000186685 Lactobacillus hilgardii Species 0.000 description 1
- 241001468190 Lactobacillus homohiochii Species 0.000 description 1
- 241001324870 Lactobacillus iners Species 0.000 description 1
- 241001343376 Lactobacillus ingluviei Species 0.000 description 1
- 241001640457 Lactobacillus intestinalis Species 0.000 description 1
- 241001561398 Lactobacillus jensenii Species 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 241000316281 Lactobacillus kalixensis Species 0.000 description 1
- 241000108055 Lactobacillus kefiranofaciens Species 0.000 description 1
- 241001468191 Lactobacillus kefiri Species 0.000 description 1
- 241000674808 Lactobacillus kitasatonis Species 0.000 description 1
- 241001339775 Lactobacillus kunkeei Species 0.000 description 1
- 241001134654 Lactobacillus leichmannii Species 0.000 description 1
- 241000520745 Lactobacillus lindneri Species 0.000 description 1
- 241000751214 Lactobacillus malefermentans Species 0.000 description 1
- 241000186851 Lactobacillus mali Species 0.000 description 1
- 241000016642 Lactobacillus manihotivorans Species 0.000 description 1
- 241000414465 Lactobacillus mindensis Species 0.000 description 1
- 241000394636 Lactobacillus mucosae Species 0.000 description 1
- 241000186871 Lactobacillus murinus Species 0.000 description 1
- 241001635183 Lactobacillus nagelii Species 0.000 description 1
- 241000468580 Lactobacillus namurensis Species 0.000 description 1
- 241000938545 Lactobacillus nantensis Species 0.000 description 1
- 241001150383 Lactobacillus oligofermentans Species 0.000 description 1
- 241000186784 Lactobacillus oris Species 0.000 description 1
- 241000216456 Lactobacillus panis Species 0.000 description 1
- 241000692795 Lactobacillus pantheris Species 0.000 description 1
- 241001105994 Lactobacillus parabrevis Species 0.000 description 1
- 241001643453 Lactobacillus parabuchneri Species 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 241000972176 Lactobacillus paracollinoides Species 0.000 description 1
- 241000831743 Lactobacillus parafarraginis Species 0.000 description 1
- 241001643449 Lactobacillus parakefiri Species 0.000 description 1
- 241000866650 Lactobacillus paraplantarum Species 0.000 description 1
- 241000186684 Lactobacillus pentosus Species 0.000 description 1
- 241001448603 Lactobacillus perolens Species 0.000 description 1
- 241001495404 Lactobacillus pontis Species 0.000 description 1
- 241000220680 Lactobacillus psittaci Species 0.000 description 1
- 241000692139 Lactobacillus rennini Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241001438705 Lactobacillus rogosae Species 0.000 description 1
- 241000602084 Lactobacillus rossiae Species 0.000 description 1
- 241000186870 Lactobacillus ruminis Species 0.000 description 1
- 241000318646 Lactobacillus saerimneri Species 0.000 description 1
- 241000186612 Lactobacillus sakei Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 241000186868 Lactobacillus sanfranciscensis Species 0.000 description 1
- 241001424195 Lactobacillus satsumensis Species 0.000 description 1
- 241000915257 Lactobacillus secaliphilus Species 0.000 description 1
- 241000186867 Lactobacillus sharpeae Species 0.000 description 1
- 241000755777 Lactobacillus siliginis Species 0.000 description 1
- 241001599932 Lactobacillus spicheri Species 0.000 description 1
- 241001643448 Lactobacillus suebicus Species 0.000 description 1
- 241000489237 Lactobacillus thailandensis Species 0.000 description 1
- 241000316280 Lactobacillus ultunensis Species 0.000 description 1
- 241000751212 Lactobacillus vaccinostercus Species 0.000 description 1
- 241000186783 Lactobacillus vaginalis Species 0.000 description 1
- 241001456524 Lactobacillus versmoldensis Species 0.000 description 1
- 241000692127 Lactobacillus vini Species 0.000 description 1
- 241000577554 Lactobacillus zeae Species 0.000 description 1
- 241000110060 Lactobacillus zymae Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- 235000019510 Long pepper Nutrition 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102100025169 Max-binding protein MNT Human genes 0.000 description 1
- 229940124887 MenHibrix Drugs 0.000 description 1
- 229940124904 Menactra Drugs 0.000 description 1
- 229940124883 Menomune A/C/Y/W-135 Drugs 0.000 description 1
- 229940124951 Menveo Drugs 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000845808 Neptuniibacter Species 0.000 description 1
- 241000605156 Nitrobacter hamburgensis Species 0.000 description 1
- 241000179039 Paenibacillus Species 0.000 description 1
- 241000194109 Paenibacillus lautus Species 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 241000192001 Pediococcus Species 0.000 description 1
- 229940124909 PedvaxHIB Drugs 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 240000003455 Piper longum Species 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229940124950 Prevnar 13 Drugs 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 241000193448 Ruminiclostridium thermocellum Species 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000204117 Sporolactobacillus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229940124929 TYPHIM Vi Drugs 0.000 description 1
- 241000019011 Tasa Species 0.000 description 1
- 241000500334 Tetragenococcus Species 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 241001291204 Thermobacillus Species 0.000 description 1
- 241000589596 Thermus Species 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 241000321595 Ureibacillus Species 0.000 description 1
- 241000207194 Vagococcus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000202221 Weissella Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229940099983 activase Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229960004470 agalsidase beta Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 108010060162 alglucerase Proteins 0.000 description 1
- 239000006720 allantoin mineral medium Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 229960000754 anthrax vaccine adsorbed Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 235000021052 average daily weight gain Nutrition 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- 241000385736 bacterium B Species 0.000 description 1
- 239000010905 bagasse Substances 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 230000009704 beneficial physiological effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229940090821 bexsero Drugs 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 229910000394 calcium triphosphate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000007374 caso agar Substances 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 229960005004 cholera vaccine Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 210000004913 chyme Anatomy 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000007381 clostridium thermocellum medium Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 108010082025 cyan fluorescent protein Proteins 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- GVGYEFKIHJTNQZ-RFQIPJPRSA-N ecgonine benzoate Chemical compound O([C@@H]1[C@@H]([C@H]2CC[C@@H](C1)N2C)C(O)=O)C(=O)C1=CC=CC=C1 GVGYEFKIHJTNQZ-RFQIPJPRSA-N 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000004070 electrodeposition Methods 0.000 description 1
- 238000000609 electron-beam lithography Methods 0.000 description 1
- KUBARPMUNHKBIQ-VTHUDJRQSA-N eliglustat tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1 KUBARPMUNHKBIQ-VTHUDJRQSA-N 0.000 description 1
- 229940073038 elspar Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229940014516 fabrazyme Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000013572 fruit purees Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 1
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003673 groundwater Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 102000043557 human IFNG Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 229960002127 imiglucerase Drugs 0.000 description 1
- 108010039650 imiglucerase Proteins 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000012994 industrial processing Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000000813 microcontact printing Methods 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000006151 minimal media Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000010812 mixed waste Substances 0.000 description 1
- 239000006936 modified chopped meat medium Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 235000012459 muffins Nutrition 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 239000006837 my medium Substances 0.000 description 1
- 238000001127 nanoimprint lithography Methods 0.000 description 1
- 230000001069 nematicidal effect Effects 0.000 description 1
- 229960001267 nesiritide Drugs 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 239000006877 oatmeal agar Substances 0.000 description 1
- 239000003305 oil spill Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 229940099216 oncaspar Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- RFWLACFDYFIVMC-UHFFFAOYSA-D pentacalcium;[oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O RFWLACFDYFIVMC-UHFFFAOYSA-D 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000005504 petroleum refining Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229940033515 pneumovax 23 Drugs 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940031937 polysaccharide vaccine Drugs 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920005749 polyurethane resin Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000007732 propionibacterium agar Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000012514 protein characterization Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 108010009004 proteose-peptone Proteins 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 229940107568 pulmozyme Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000005067 remediation Methods 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229940115037 santyl Drugs 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000004460 silage Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000013570 smoothie Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 238000002174 soft lithography Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000007245 sour dough medium Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 239000002352 surface water Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 101150051767 tasA gene Proteins 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940110675 theracys Drugs 0.000 description 1
- 239000007126 thermus medium Substances 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229940035144 trumenba Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 239000010455 vermiculite Substances 0.000 description 1
- 229910052902 vermiculite Inorganic materials 0.000 description 1
- 235000019354 vermiculite Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
- C12R2001/125—Bacillus subtilis ; Hay bacillus; Grass bacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Definitions
- the present invention in some embodiments thereof, relates to methods of generating bacterial compositions, more particularly, but not exclusively, to probiotic compositions, those beneficial to the environment and those used in industry.
- probiotics Living microbial cells which are administered in adequate amounts, confer a beneficial physiological effect on the host, are known as "probiotics". Studies have shown therapeutic effects that probiotic bacteria can provide to the host in maintaining a healthy gut and controlling several types of gastrointestinal infections. Due to their perceived health benefits, probiotic bacteria have been increasingly incorporated into a variety of food and drink products during the last few decades. Some of the most common types of microorganisms used as probiotics are the lactic acid bacteria (LAB), which mainly belong to the genera Lactobacillus and Bifidobacterium. Both these genera are dominant inhabitants in the human intestine and have a long history of safe use and are considered as GRAS (generally recognized as safe).
- LAB lactic acid bacteria
- probiotics are usually available as dry bacterial powders prepared mainly by freeze drying which has been established as a procedure that may cause fatal injury to cells. Therefore, there is a need to develop novel technologies aimed to improve the survival of health-promoting bacteria during food production, as well as through the storage and ingestion processes in order to maintain delivery of probiotics to humans.
- biofilm In most natural ecosystems, bacteria prefer to grow in complex community of multicellular cells called biofilm and not as free-living (planktonic) cells. Biofilm mode of growth is preferable also for bacteria that inhabit the intestinal tract. Cells in a biofilm are bound together by an extracellular matrix that mainly consists of polysaccharides and other macromolecules such as proteins, DNA, lipids and nucleic acids, which are produced by the cells themselves. Interactions between the species embedded in the biofilm and their environment result in the formation of a complex structure, capable of resisting to environmental stress and exposure to antimicrobial agents. Thus, biofilm formation represents a strategy for persistence under unfavorable conditions in diverse environments.
- Bacillus subtilis a spore-forming nonpathogenic bacterium, which is characterized by its ability to produce a robust biofilm.
- Bacillus species principally B. subtilis, have gained recent interest as probiotic microorganism since they were shown to positively effect on host health status mainly by keeping a favorable balance of microflora in the gastrointestinal tract. Since B. subtilis spores are capable of surviving extreme pH conditions and low oxygen, high numbers of dormant but viable microbes may reach the lower intestine which may induce some beneficial effects through secretion of active substances. Furthermore, it was found that B.
- subtilis cells enhance growth and viability of lactobacilli spp., possibly through the production of catalase and subtilisin (Hosoi, Ametani, Kiuchi, & Kaminogawa, 2000). It has also been reported that T- polyglutamic acid produced by B. subtilis as part of an extracellular matrix could be used to improve the survival of probiotic bacteria during freeze drying (A. R. Bhat et al., 2013) and during storage (A. R. Bhat et al., 2015). Likewise, during simulated gastric juice which simulated the acidic conditions of the stomach (A. R. Bhat et al., 2015).
- a method of preparing a bacterial composition comprising:
- a bacterial composition obtainable according to the methods described herein.
- a food/feed product comprising the bacterial composition described herein.
- a method of improving or maintaining the health of a subject comprising administering to the subject a therapeutically effective amount of the probiotic composition described herein, thereby improving or maintaining the health of the subject.
- a method of selecting an agent or culturing condition which is advantageous for preparing a bacterial composition the method comprising co-culturing beneficial bacteria with biofilm-producing bacteria in a growth substrate in the presence of the agent or under the culturing condition, so as to generate a biofilm comprising the beneficial bacteria and the biofilm-producing bacteria, wherein a change in a property of the biofilm is indicative of the agent or culturing condition being advantageous for preparing the bacterial composition.
- the biofilm-producing bacteria are non-pathogenic bacteria.
- the biofilm-producing bacteria are of the bacillus genus.
- the biofilm-producing bacteria are of the B. subtilis species.
- the biofilm-producing bacteria are of the strain 127185/2.
- the growth substrate comprises manganese.
- the growth substrate comprises dextrose.
- the growth substrate comprises manganese.
- the beneficial bacteria are probiotic bacteria.
- the beneficial bacteria are genetically modified to express a therapeutic polypeptide.
- the probiotic bacteria is of the lactobacillales order.
- the biofilm-producing bacteria are of the B. subtilis species.
- the probiotic bacteria are of the L. plantarum species.
- the beneficial bacteria are used in bioremediation.
- the biofilm-producing bacteria express genes of the KinD-SpoOA pathway.
- the growth substrate comprises a growth medium.
- the growth medium is selected from the group consisting of LB, LBGM, milk and MRS.
- the biofilm-producing bacteria are of the bacillus genus and the beneficial bacteria are of the lactobaciUales order, the growth substrate is LBGM, milk or MRS.
- the growth substrate is MRS.
- the conditions comprise a pH of 6.8-
- the growth substrate comprises acetoin.
- the method further comprises dehydrating the biofilm following the isolating.
- the beneficial bacteria comprises no more than 50 bacterial species.
- biofilm-producing bacteria are a single species of biofilm-producing bacteria.
- At least 50 % of the bacteria in the composition are viable.
- the bacterial composition comprises no more than 50 bacterial species of beneficial bacteria.
- the bacterial composition comprises a single species of non-pathogenic bacteria.
- the bacterial composition is edible.
- the bacterial composition is a probiotic bacterial composition.
- the bacterial composition is formulated as a powder, a liquid or a tablet.
- the biofilm-producing bacteria are of the bacillus genus.
- the biofilm-producing bacteria are of the B. subtilis species.
- the beneficial bacteria are probiotic bacteria.
- the probiotic bacteria are of the lactobacillales order.
- the agent alters the pH of a medium of the system.
- FIGs. 1A-B are graphs comparing B. subtilis and L. plantarum growth in co-culture.
- the co-culture generation had no effect on L. plantarum and B. subtilis growth (compared to their growth in pure culture), indicating that there are no antagonistic interactions between these bacteria.
- FIG. 2 are photographs illustrating that modified MRS medium triggers biofilm formation by B. subtilis.
- the effect of the pH modification of MRS on B. subtilis NCIB3610 biofilm formation was analyzed using stereoscopic microscope.
- FIG. 3 are photographs illustrating that the combination of LB with MRS medium triggers biofilm development by B. subtilis.
- FIGs. 4A-B are graphs illustrating that the combination of LB with MRS medium triggers extracellular matrix production by B. subtilis. Increasing MRS concentration induces transcription of tapA-sipW-tasA (A) and epsA-0 (B) operons.
- FIG. 5A are photographs illustrating that the biofilm stimulating effect of MRS is regulated by the matrix synthesis and biofilm forming signaling pathway previously described in B. subtilis.
- Colony development and pellicle formation on MRS (pH 7) by the wild type (WT) and various mutant strains were compared.
- the strains used here were as follows: wild type (NCIB3610), AkinCD (RL4577), AkinAB (RL4573), AspoOA (RL4620), AepsAtasA (RL4566), AabrB (YC668).
- FIG. 5B are photographs illustrating that the effect of MRS in WT cells is comparable to the matrix overproducing mutant cells ⁇ AabrB) in B. subtilis.
- FIG. 6 are photographs illustrating that MRS induces colony biofilm formation in different Bacillus species.
- MRS (pH 7) medium strongly induced colony type biofilm formation of B. paralicheniformis MS303, B. licheniformis MS310, B. licheniformis S 127, B. subtilis
- FIG. 7 are photographs illustrating that MRS induces pellicle formation in different Bacillus species.
- MRS (pH 7) medium strongly induced pellicle formation of B. paralicheniformis MS303, B. licheniformis MS310, B. licheniformis S 127, B. subtilis MS 1577 and fi. cereus 10987.
- FIGs. 8A-B are images illustrating that B. subtilis produces extracellular matrix whilst forming a dual-species biofilm with L. plantarum.
- 8A CLSM images of co-culture biofilm of B. subtilis and L. plantarum in MRS pH 7 at 37 °C and 50 rpm. From left to right: images made using fluorescent light, Nomarski differential interference contrast (DIC) and merged image. Top panel shows the expression of fluorescently tagged B. subtilis cells constitutively express GFP. Bottom panel shows expression of matrix producing B. subtilis cells express CFP under the control of tapA promoter. In all images L. plantarum cells are not stained. 8B. CLSM images of co-culture biofilm of B. subtilis and L. plantarum in LBGM medium.
- DIC Nomarski differential interference contrast
- FIGs. 9A-C are SEM images of (A) B. subtilis cells, (B) L. plantarum cells and (C) dual species biofilm composed of B. subtilis and L. plantarum.
- FIGs. 10A-B are graphs illustrating that dual species biofilm facilitates survival of L. plantarum exposed to unfavorable conditions. Survival of L. plantarum cells in presence or absence (control) of B. subtilis biofilm were determined during (A) heat treatment at 63 °C 1 to 3 min (B) storage at 4 °C for 21 days. The values presented are the average of at least three independent experiments performed in duplicates. *p ⁇ 0.05
- FIGs. 11A-B are graphs illustrating that the extracellular matrix of B. subtilis facilitates increased survival of L. plantarum during heat treatment.
- A The effect of heat treatment at 63 °C for 3 min on WT B. subtilis and its derivatives, a mutant deficient in exopolysaccharide component and protein component of extracellular matrix ⁇ AepsAtasA) and a mutant deficient in a repressor of the matrix genes (AabrB; overproduces biofilm matrix) was tested. The results presented are the average of at least three independent experiments performed in duplicates. *p ⁇ 0.05.
- B The samples were grown in milk for 18 h at 30 °C, 20 rpm. Afterwards they were heat treated at 63 °C for 1 to 3 minutes. Control samples were not heat-treated. The number of viable L. plantarum cells was determined using CFU-method. *p ⁇ 0.05
- FIG. 12 is a graph illustrating that the presence of B. subtilis biofilm increases survival of L. plantarum during gastric and intestinal digestion in vitro (model system). Survival of L. plantarum cells in presence or absence (control) of B. subtilis biofilm were determined during gastro-intestinal digestion in vitro. The results presented are the average of three independent experiments performed in duplicates. *p ⁇ 0.05
- FIG. 13 is a graph of the growth curves of B. subtilis 3610NCIB in MRS (pH 7) and LB.
- FIG. 14 are photographs illustrating the effect of mutations in Histidine kinases on colony surface architecture and pellicle formation in MRS pH 7.
- FIGs. 16A-B are photographs illustrating that acetoin triggers the colony type biofilm formation by Bacillus subtilis
- FIGs. 17A-D are photographs illustrating that the transcription of the tapA operon responsible for the matrix production in B. subtilis is highly upregulated by acetoin.
- FIGs. 18A-B are photographs depicting the biofilm generated from the B. subtilis strains NCIB3610 and 127185/2 respectively.
- FIG. 20 is a graph illustrating the survival of L. plantarum grown in co-culture biofilm with B. subtilis in exposure to high acidity level.
- the sign '+' in the tested cultures indicates a growth with 50 rpm shaking, while the sign '-' indicates a growth without shaking at all.
- the co-cultures of L. plantarum and B. subtilis showed a lower decrease in the survival rates of L. plantarum (compared to the mono- culture of L. plantarum) in transition to an acidic environment as with as well as without shaking.
- FIG. 21 are photographs illustrating that Mn 2+ ions are involved in biofilm formation by
- B. subtilis in modified MRS Effects of exclusion of certain MRS medium components (Mg 2+ , Mn 2+ , sodium acetate, dipotassium phosphate, dextrose, ammonium citrate) on colony development and pellicle formation by the WT B. subtilis cells were observed.
- MRS medium components Mg 2+ , Mn 2+ , sodium acetate, dipotassium phosphate, dextrose, ammonium citrate
- the present invention in some embodiments thereof, relates to methods of generating bacterial compositions, more particularly, but not exclusively, to probiotic compositions, those beneficial to the environment and those used in industry.
- Bacteria are economically important as these microorganisms are used by humans for many purposes.
- the beneficial uses of bacteria include the production of traditional foods such as yoghurt, cheese, and vinegar; biotechnology and genetic engineering, producing substances such as drugs and vitamins; agriculture; fibre retting; production of methane; bioremediation and biological control of pests.
- probiotics are usually available as dry bacterial powders prepared mainly by freeze drying which has been established as a procedure that may cause fatal injury to cells.
- the present inventors co-cultured bacteria of the B. subtilis species together with the probiotic bacteria L. plantarum. They showed that under particular conditions the B. subtilis bacteria generated a biofilm in which the L. plantarum cells were incorporated within the extracellular matrix thereof (Figure 9 A).
- the biofilm-incorporated L. plantarum were shown to be both more heat-resistant and more cold-resistant, and further more acid-resistant than control, non-biofilm incorporated L. plantarum.
- biofilm-producing bacteria can be used to encapsulate a non-biofilm producing bacteria.
- the biofilm-producing bacteria serve as a protective carrier for the beneficial, non-biofilm producing bacteria.
- a method of preparing a bacterial composition comprising:
- bacteria refers to a prokaryotic microorganism, including archaea.
- the bacteria may be gram positive or gram negative.
- the bacteria may also be photosynthetic bacteria (e.g. cyanobacteria).
- waste bacteria refers to any bacteria that bring about a positive effect on human beings.
- the beneficial bacteria do not produce a biofilm when propagated as a monoculture in a growth medium under standard culturing conditions. In another embodiment, the beneficial bacteria do not produce a biofilm when propagated as a monoculture in a growth medium under culturing conditions that are optimal for their propagation.
- the beneficial-bacteria utilize the KinD-SpoOA pathway (for example express the genes histidine kinase kinD, spoOF, spoOB and/or spoOA) - see for example Shemesh and Chai, 2013 Journal of Bacteriology, 2013, Vol 195, No.12 pages 2747-2754, the contents of which are incorporated herein by reference.
- KinD-SpoOA pathway for example express the genes histidine kinase kinD, spoOF, spoOB and/or spoOA
- the beneficial bacteria may be one that is typically cultured in Man, Rogosa and Sharpe medium, MRS (solidified using agar or MRS broth).
- the beneficial bacteria should typically not prevent (i.e. antagonize) the biofilm-forming capability of the biofilm-generating bacteria (e.g. B. subtilis). Methods of determining whether bacteria have antagonistic activity towards other bacteria when cultured together are known in the art (see for example Figures 1A-B). In one embodiment, the beneficial bacteria are not soil bacteria.
- any number of strains of beneficial bacteria may be cultured in the co -culture of this aspect of the present invention.
- no more than 500 different strains of beneficial bacteria are cultured in a single culture
- no more than 250 different strains of beneficial bacteria are cultured in a single culture
- no more than 100 different strains of beneficial bacteria are cultured in a single culture
- no more than 90 different strains of beneficial bacteria are cultured in a single culture
- no more than 80 different strains of beneficial bacteria are cultured in a single culture
- no more than 70 different strains of beneficial bacteria are cultured in a single culture
- no more than 60 different strains of beneficial bacteria are cultured in a single culture
- no more than 50 different strains of beneficial bacteria are cultured in a single culture
- no more than 40 different strains of beneficial bacteria are cultured in a single culture
- no more than 30 different strains of beneficial bacteria are cultured in a single culture
- no more than 20 different strains of beneficial bacteria are cultured in a single culture
- the beneficial bacterial strains of a single culture of this aspect of the present invention may belong to a single species or may belong to multiple species.
- the beneficial bacterial strains of a culture may belong to a single species of bacteria.
- multiple species of beneficial bacteria are cultured on a single culture.
- no more than 10 different species of beneficial bacteria are cultured in a single culture, no more than 9 different species of beneficial bacteria are cultured in a single culture, no more than 8 different species of beneficial bacteria are cultured in a single culture, no more than 7 different species of beneficial bacteria are cultured in a single culture, no more than 6 different species of beneficial bacteria are cultured in a single culture, no more than 5 different species of beneficial bacteria are cultured in a single culture, no more than 4 different species of beneficial bacteria are cultured in a single culture, no more than 3 different species of beneficial bacteria are cultured in a single culture, no more than 2 different species of beneficial bacteria are cultured in a single culture only one species of beneficial bacteria is cultured per single culture.
- the beneficial bacteria when ingested promote the health of a human being.
- the beneficial bacteria are used in industry to generate a product that is useful for human beings (e.g. methane, petroleum, insecticide etc.).
- the beneficial bacteria are used in the food industry.
- the beneficial bacteria are used in a silage inoculant.
- the beneficial bacteria are used in agriculture to support the growth of plants.
- the beneficial bacteria are used in bioremediation.
- the beneficial bacteria are probiotic bacteria.
- probiotic bacteria refers to live bacteria which when administered in adequate amounts confer a health benefit on the host (e.g. human).
- enteric pathogens by the production of lactic acid, hydrogen peroxide and bacteriocins; competitive exclusion of enteric pathogens by blocking adhesion sites, competition for nutrients and modulation of the immune system, including inflammation reduction. They also provide benefits to the host, such as lactose intolerance alleviation; cholesterol decrease by assimilation, sustenance of the intestinal normal microbiota and dysbiosis ameliorating suppression of toxin production, degradation of toxin receptors in the intestine, preservation of normal intestinal pH, increase intestinal motility and help to maintain the integrity of the intestine permeability.
- the beneficial bacteria belong to the order Lactobacillales (commonly known as lactic acid bacteria (LAB)). These bacteria are Gram-positive, low-GC, acid-tolerant, generally nonsporulating, non-respiring, either rod- or coccus-shaped bacteria that share common metabolic and physiological characteristics. These bacteria produce lactic acid as the major metabolic end product of carbohydrate fermentation.
- LAB lactic acid bacteria
- the beneficial bacteria of the Lactobacillales order are ones which grow (and are typically cultured) in MRS agar (MRS).
- MRS agar MRS agar
- Exemplary contemplated genera of the order Lactobacillales include, but are not limited to Lactobacillus, Leuconostoc, Pediococcus, Lactococcus, Streptococcus, Aerococcus, Carnobacterium, Enterococcus, Oenococcus, Sporolactobacillus, Tetragenococcus, Vagococcus, and Weissella.
- the beneficial bacteria of this aspect of the present invention belong to the genus lactobacillus.
- Exemplary species of lactobacillus contemplated by the present invention include but are not limited to L. acetotolerans, L. acidifarinae, L. acidipiscis, L. acidophilus, L. agilis, L. algidus, L. alimentarius, L. amylolyticus, L. amylophilus,
- the species of lactobacillus is L. plantarum.
- the beneficial bacteria of this aspect of the present invention may generate a fermentation product.
- fermentation products include but are not limited to pre-biotics, biofuels, methanol, ethanol, propanol, butanol, alcohol fuels, proteins, recombinant proteins, vitamins, amino acids, organic acids (for e.g. lactic acid, propionic acid, acetic acid, succinic acid, malic acid, glutamic acid, aspartic acid and 3-hydroxypropionic acid), enzymes, antigens, antibiotics, organic chemicals, bioremediation treatments, preservatives and metabolites.
- the beneficial bacteria may be genetically modified to express a beneficial polypeptide.
- the beneficial polypeptides may be intracellular polypeptides (e.g., a cytosolic protein), transmembrane polypeptides, or secreted polypeptides. Heterologous production of proteins is widely employed in research and industrial settings, for example, for production of therapeutics, vaccines, diagnostics, biofuels, and many other applications of interest.
- Exemplary therapeutic proteins that can be produced by employing the subject compositions and methods, include but are not limited to certain native and recombinant human hormones (e.g., insulin, growth hormone, insulin-like growth factor 1, follicle- stimulating hormone, and chorionic gonadotropin), hematopoietic proteins (e.g., erythropoietin, C-CSF, GM-CSF, and IL-11), thrombotic and hematostatic proteins (e.g., tissue plasminogen activator and activated protein C), immunological proteins (e.g., interleukin), antibodies and other enzymes (e.g., deoxyribonuclease I).
- human hormones e.g., insulin, growth hormone, insulin-like growth factor 1, follicle- stimulating hormone, and chorionic gonadotropin
- hematopoietic proteins e.g., erythropoietin, C-CSF, GM-CSF, and
- Exemplary vaccines that can be produced by the subject compositions and methods include but are not limited to vaccines against various influenza viruses (e.g., types A, B and C and the various serotypes for each type such as H5N2, H1N1, H3N2 for type A influenza viruses), HIV, hepatitis viruses (e.g., hepatitis A, B, C or D), Lyme disease, and human papillomavirus (HPV).
- examples of heterologously produced protein diagnostics include but are not limited to secretin, thyroid stimulating hormone (TSH), HIV antigens, and hepatitis C antigens.
- Proteins or peptides produced by the heterologous polypeptides can include, but are not limited to cytokines, chemokines, lymphokines, ligands, receptors, hormones, enzymes, antibodies and antibody fragments, and growth factors.
- Non-limiting examples of receptors include TNF type I receptor, IL-1 receptor type II, IL-1 receptor antagonist, IL-4 receptor and any chemically or genetically modified soluble receptors.
- enzymes include acetylcholinesterase, lactase, activated protein C, factor VII, collagenase (e.g., marketed by Advance Biofactures Corporation under the name Santyl); agalsidase-beta (e.g., marketed by Genzyme under the name Fabrazyme); dornase-alpha (e.g., marketed by Genentech under the name Pulmozyme);reteplase (e.g., marketed by Genentech under the name Activase); pegylated- asparaginase (e.g., marketed by Enzon under the name Oncaspar); asparaginase (e.g., marketed by Merck under the name Elspar); and imiglucerase (e.g., marketed by Genzyme under the name Ceredase).
- acetylcholinesterase lactase, activated protein C, factor VII, collagenase
- polypeptides or proteins include, but are not limited to granulocyte macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), macrophage colony stimulating factor (M-CSF), colony stimulating factor (CSF), interferon beta (IFN-beta), interferon gamma (IFNgamma), interferon gamma inducing factor I (IGIF), transforming growth factor beta (IGF-beta), RANTES (regulated upon activation, normal T-cell expressed and presumably secreted), macrophage inflammatory proteins (e.g., MIP-1-alpha and MIP-1-beta), Leishmnania elongation initiating factor (LEIF), platelet derived growth factor (PDGF), tumor necrosis factor (TNF), growth factors, e.g., epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), fibroblast growth factor, (FGF), nerve growth factor (NGF), brain
- the gpl20 glycoprotein is a human immunodeficiency virus (WIV) envelope protein, and the gpl60 glycoprotein is a known precursor to the gpl20 glycoprotein.
- WIV human immunodeficiency virus
- Other examples include secretin, nesiritide (human B-type natriuretic peptide (hBNP)) and GYP-I.
- Contemplated bacteria for the expression of human interferon beta lb include for example E.coli.
- Contemplated bacteria for the expression of human interferon gamma include for example E.coli.
- Contemplated bacteria for the expression of human growth hormone include for example
- Contemplated bacteria for the expression of human insulin include for example E.coli.
- Contemplated bacteria for the expression of interleukin II include for example E.coli.
- the beneficial polypeptide is an antibody (e.g. Humira, Remicade, Rituxan, Enbrel, Avastin, Herceptin).
- an antibody e.g. Humira, Remicade, Rituxan, Enbrel, Avastin, Herceptin.
- Contemplated bacteria for the expression of antibodies include for example E.coli, Bacillus brevis, Bacillus subtilis and Bacillus megaterium.
- exemplary vaccines contemplated by the present invention include, but are not limited to Vivotif Berna Vaccine (typhoid vaccine, live), Prevnar 13 (pneumococcal 13- valent vaccine), Menactra (meningococcal conjugate vaccine), ActHIB (haemophilus b conjugate (prp-t) vaccine), Bexsero (meningococcal group B vaccine), Biothrax (anthrax vaccine adsorbed), Hiberix (haemophilus b conjugate (prp-t) vaccine), HibTITER (haemophilus b conjugate (hboc) vaccine), Liquid PedvaxHIB (haemophilus b conjugate (prp-omp) vaccine), MenHibrix (haemophilus b conjugate (prp-t) vaccine/meningococcal conjugate vaccine), Menomune A / C / Y
- contemplated beneficial bacteria are those that are useful in bioremediation. Such remediation includes heavy metals, chemical, radiation and hydrocarbon contamination.
- bacteria examples include bacteria that may be used for bioremediation.
- Pseudomonas putida is a gram-negative soil bacterium that is involved in the bioremediation of toluene, a component of paint thinner. It is also capable of degrading naphthalene, a product of petroleum refining, in contaminated soils.
- Dechloromonas aromatica is a rod-shaped bacterium which can oxidize aromatics including benzoate, chlorobenzoate, and toluene, coupling the reaction with the reduction of oxygen, chlorate, or nitrate. It is the only organism able to oxidize benzene anaerobically. Due to the high propensity of benzene contamination, especially in ground and surface water, D. aromatic is especially useful for in situ bioremediation of this substance.
- Nitrifiers and Denitrifiers Industrial bioremediation is used to clean wastewater. Most treatment systems rely on microbial activity to remove unwanted mineral nitrogen compounds (i.e. ammonia, nitrite, nitrate). The removal of nitrogen is a two stage process that involves nitrification and denitrification. During nitrification, ammonium is oxidized to nitrite by organisms like Nitrosomonas europaea. Then, nitrite is further oxidized to nitrate by microbes like Nitrobacter hamburgensis. In anaerobic conditions, nitrate produced during ammonium oxidation is used as a terminal electron acceptor by microbes like Paracoccus denitrificans . The result is N2 gas. Through this process, ammonium and nitrate, two pollutants responsible for eutrophication in natural waters, are remediated.
- nitrogen compounds i.e. ammonia, nitrite, nitrate
- Deinococcus radiodurans is a radiation-resistant extremophile bacterium that is genetically engineered for the bioremediation of solvents and heavy metals.
- An engineered strain of Deinococcus radiodurans has been shown to degrade ionic mercury and toluene in radioactive mixed waste environments.
- nitrate produced during ammonium oxidation is used as a terminal electron acceptor by microbes like Paracoccus denitrificans . The result is dinitrogen gas. Through this process, ammonium and nitrate, two pollutants responsible for eutrophication in natural waters, are remediated.
- Methylibium petroleiphilum (formally known as PM1 strain) is a bacterium capable of methyl tert-butyl ether (MTBE) bioremediation. PM1 degrades MTBE by using the contaminant as the sole carbon and energy source.
- PM1 strain Methylibium petroleiphilum (formally known as PM1 strain) is a bacterium capable of methyl tert-butyl ether (MTBE) bioremediation. PM1 degrades MTBE by using the contaminant as the sole carbon and energy source.
- MTBE methyl tert-butyl ether
- Alcanivorax borkumensis is a marine rod-shaped bacterium which consumes hydrocarbons, such as the ones found in fuel, and produces carbon dioxide. It grows rapidly in environments damaged by oil, and has been used to aid in cleaning the more than 830,000 gallons of oil from the Deepwater Horizon oil spill in the Gulf of Mexico.
- Other contemplated bacteria that can be used to clean up oil include Colwellia and Neptuniibacter.
- the method of this aspect of the present invention contemplates culturing the beneficial bacteria with a biofilm-producing bacteria.
- biofilm refers to a community of bacteria that are comprised
- extracellular polymeric substances typically include exopolysaccharides (such as those synthesized by the products of the epsA-0 operon) and amyloid fibers (such as those encoded by tapA-sipW-tasA operon).
- the matrix typically comprises extracellular DNA and protein, as well as carbohydrates.
- biofilm-producing bacteria may also be beneficial bacteria.
- biofilm-producing bacteria are typically of a different order and/or genus than the beneficial bacteria which are incorporated into the biofilm.
- the biofilm-producing bacteria and the beneficial bacteria may be of distinct strains, species, genus and/or order.
- the biofilm-producing bacteria is non-pathogenic (i.e. do not cause physical harm to, or disease in) a human being.
- any number of strains of biofilm-producing bacteria may be cultured in the co-culture of this aspect of the present invention.
- no more than 500 different strains of biofilm-producing bacteria are cultured in a single culture
- no more than 250 different strains of biofilm-producing bacteria are cultured in a single culture
- no more than 100 different strains of biofilm-producing bacteria are cultured in a single culture
- no more than 90 different strains of biofilm-producing bacteria are cultured in a single culture
- no more than 80 different strains of biofilm- bacteria are cultured in a single culture
- no more than 70 different strains of biofilm- producing bacteria are cultured in a single culture
- no more than 60 different strains of biofilm- producing bacteria are cultured in a single culture
- no more than 50 different strains of biofilm- producing bacteria are cultured in a single culture
- no more than 40 different strains of biofilm- producing bacteria are cultured in a single culture
- no more than 30 different strains of biofilm- producing bacteria are cultured in
- biofilm-producing bacterial strains of a single culture of this aspect of the present invention may belong to a single species or may belong to multiple species.
- the biofilm-producing bacterial strains of a culture belong to a single species of bacteria.
- multiple species of biofilm-producing bacteria are cultured on a single culture.
- no more than 10 different species of biofilm-producing bacteria are cultured in a single culture, no more than 9 different species of biofilm-producing bacteria are cultured in a single culture, no more than 8 different species of biofilm-producing bacteria are cultured in a single culture, no more than 7 different species of biofilm-producing bacteria are cultured in a single culture, no more than 6 different species of biofilm-producing bacteria are cultured in a single culture, no more than 5 different species of biofilm-producing bacteria are cultured in a single culture, no more than 4 different species of biofilm-producing bacteria are cultured in a single culture, no more than 3 different species of biofilm-producing bacteria are cultured in a single culture, no more than 2 different species of biofilm-producing bacteria are cultured in a single culture or only one species of biofilm-producing bacteria is cultured per single culture.
- the biofilm-producing bacteria belong to the genus Bacillus.
- the genus Bacillus includes all members known to those of skill in the art, including but not limited to B. subtilis, B. licheniformis, B. lentus, B. brevis, B. stearothermophilus, B. alkalophilus, B. amyloliquefaciens, B. clausii, B. halodurans, B. megaterium, B. coagulans, B. circulans, B. lautus, and B. thuringiensis . It is recognized that the genus Bacillus continues to undergo taxonomical reorganization. Thus, it is intended that the genus include species that have been reclassified, including but not limited to such organisms as B.
- stearothermophilus which is now named "Geobacillus stearothermophilus.”
- the production of resistant endospores in the presence of oxygen is considered the defining feature of the genus Bacillus, although this characteristic also applies to the recently named Alicyclobacillus, Amphibacillus, Aneurinibacillus, Anoxybacillus, Brevibacillus, Filobacillus, Gracilibacillus, Halobacillus, Paenibacillus, Salibacillus, Thermobacillus, Ureibacillus, and Virgibacillus .
- the biofilm-producing bacteria are of the species B. subtilis.
- Exemplary strains of B. subtilis contemplated by the present invention include, but are not limited to B. subtilis MS 1577 and 127185/2 (MS302; dairy isolate) and NCIB3610.
- Exemplary strains of B paralicheniformis contemplated by the present invention include, but are not limited to B. paralicheniformis MS303, and B. paralicheniformis S 127.
- Exemplary strains of B.licheniformis contemplated by the present invention include, but are not limited to B.licheniformis MS310, and B. licheniformis MS307.
- the biofilm-producing bacteria does not comprise the species B. cereus.
- both the beneficial culture and the biofilm- generating culture are cultured separately to generate a starter culture.
- the medium and conditions of the starter culture are typically selected so as to optimize growth of each of the bacteria.
- Contemplated started cultures include a dried starter culture, a dehydrated starter culture, a frozen starter culture, or a concentrated starter culture.
- the starter culture is grown for at least two hours, 4 hours, 8 hours, 12 hours until a sufficient amount of bacteria are propagated.
- the method includes a method of co-culturing, whereby the beneficial bacteria is of the genus lactobacillus (e.g. the species L. plantarum) and the biofilm-producing bacteria is of the genus Bacillus (e.g. of the species B. subtilis).
- the beneficial bacteria is of the genus lactobacillus (e.g. the species L. plantarum) and the biofilm-producing bacteria is of the genus Bacillus (e.g. of the species B. subtilis).
- the method of co-culturing the beneficial bacteria with the biofilm producing bacteria is selected such that it enables the proliferation of both types of microorganisms and incorporation of both microorganisms into the biofilm.
- the co-culturing is carried out in (or on) a growth substrate that is typically used to culture the beneficial bacteria.
- the growth substrate may be a solid or a liquid medium.
- the co-culture is shaken during the culturing.
- growth substrates examples include but are not limited to MRS medium, LB medium, TBS medium, yeast extract, soy peptone, casein peptone and meat peptone.
- Abiotrophia media Recipe for medium appropriate for growth of Abiotrophia genus Acetamide
- Medium - Recipe for Acetamide medium.
- Agrobacterium Agar Recipe - Agar appropriate for growth of Agrobacterium genus
- Ashbya Full Medium Recipe for the production of Ashbya full medium.
- Azotobacter Agar - Agar appropriate for growth of Azobacter genus
- Bennett's Medium - media used for growth of some Actinoplanes species Bennett's Medium - media used for growth of some Actinoplanes species.
- Bacillus agar - Agar used to grow some Bacillus species.
- Bifidobacterium Medium Recipe for Bifidobacterium medium.
- Brain Heart Infusion Glucose Agar Recipe for Brain Heart Infusion Glucose Agar.
- Cantharellus Agar Recipe - Recipe for Cantharellus agar.
- Clostridium thermocellum Medium - Recipe for medium appropriate for growth of Clostridium thermocellum
- Creatinine Medium Recipe for the production of creatinine medium.
- CZA Czapek Agar
- CZA Czapek Agar
- Desulfovibrio Medium Recipe for Desulfovibrio Medium.
- Glucose Yeast Extract Agar - Recipe for Glucose Yeast Extract Agar.
- Halobacterium agar - Recipe for the preparation of Halobacterium Halobacteria Medium - Recipe for Halobacteria Medium.
- Marine agar - Recipe for marine agar Used for the growth of several marine bacteria.
- Marine broth - Recipe for marine broth Used for the growth of several marine bacteria.
- Methylamine Salts Agar - Recipe for methylamine salts
- Methylamine Salts Medium - Recipe for methylamine salts medium
- Modified Chopped Meat Medium Used for the growth of several anaerobic bacteria.
- MY medium - Maltose yeast extract bacterial growth medium Maltose yeast extract bacterial growth medium.
- N4 Mineral Medium - Recipe for the production of N4 mineral medium
- Nitrosomonas europaea medium Recipe for the production of Nitrosomonas europaea medium.
- Nutrient agar - Recipe for nutrient agar suitable for growth of many bacterial species Nutrient broth - Recipe for nutrient broth suitable for growth of many bacterial species.
- MRS media - Recipe for MRS media MRS media has been used for the recovery of lactic acid bacteria (LAB) from various food products.
- LAB lactic acid bacteria
- NZCYM - NZ amine NaCl
- bacto-yeast extract NaCl
- casamino acids and magnesium sulfate.
- NZM - NZ amine, NaCl, and magnesium sulfate NZM - NZ amine, NaCl, and magnesium sulfate.
- NZYM - NZ amine NaCl
- bacto-yeast extract magnesium sulfate
- Oenococcus Medium Recipe for the preparation of Oenococcus medium.
- Osmophilic Medium Recipe for Osmophilic Medium.
- Propionibacterium Agar Recipe - Agar appropriate for the growth of Propionibacterium.
- Propionibacterium Medium Recipe - Medium appropriate for the growth of Propionibacterium.
- PYS agar - agar used to grow some Actinomadura species.
- Starch - Mineral Salt (STMS) Agar - Recipe for starch - mineral salt (STMS) agar.
- Styrene Mineral Salts Medium - Recipe for Styrene Mineral Salts medium.
- Tomato Juice Medium Recipe for the preparation of tomato juice medium.
- Tomato Juice Yeast Extract Agar - Recipe for the preparation of tomato juice yeast extract agar.
- Tomato Juice Yeast Extract Medium Recipe for the preparation of tomato juice yeast extract medium.
- TSY agar - Trypticase soy yeast agar Recipe TSY broth - Trypticase soy yeast broth Recipe.
- TYG Medium Tryptone, yeast, glucose bacterial growth medium.
- TYX Medium Tryptone, yeast, xylose bacterial growth medium.
- YMG agar - Recipe for yeast and malt extract with glucose agar This agar is used for a number of Streptomyces species.
- YMG media - Recipe for yeast and malt extract with glucose media This media is used for a number of Streptomyces species.
- YPD media - Yeast extract/peptone/dextrose bacterial media YPD media - Yeast extract/peptone/dextrose bacterial media.
- the co-culture may be carried out in a growth substrate which comprises LBGM, milk or MRS.
- LBGM genus lactobacillus
- Other media that can be used to generate the co-culture of the present invention include MSgg minimal medium (Shemesh, M., et al (2010). Bacteriol 192, 6352-6356); LB enriched with lactose: Duanis-Assaf D., et al (2016) Front. Microbiol.
- the culturing conditions are selected that encourage incorporation of both the different bacteria into the biofilm.
- the present inventors have uncovered particular components of a growth medium that are important for biofilm generation of bacteria being of the genus Bacillus (e.g. of the species B. subtilis) - see Figure 21.
- the medium used for co- culturing a beneficial bacteria with Bacillus bacteria comprises manganese.
- the medium comprises dextrose.
- the medium used for co-culturing comprises both manganese and dextrose.
- a method of selecting an agent or culturing condition which is advantageous for preparing a bacterial composition comprising co-culturing beneficial bacteria with a biofilm-producing bacteria in a growth substrate in the presence of the agent or under the culturing condition so as to generate a biofilm comprising the beneficial bacteria and the biofilm-producing bacteria, wherein a change in a property of the biofilm is indicative of the agent or culturing condition being advantageous for preparing the bacterial composition.
- Exemplary conditions of the co-culture that may be altered include the properties of the surface on which the culture is carried out (for example the surface chemistry of the solid surface, including but not limited to functional groups, electrostatic charge, coating; surface roughness, surface topography, including but not limited to grooves, cavities, ridges, pores, hexagonally packed (HP) pillars, equilateral triangles surrounded by HP pillars, and the Sharklet topography etc.).
- the solid surface may be of a defined geometry and/or topography such that it promotes encapsulation/incorporation of the beneficial bacteria into the biofilm.
- the solid surface may be of a defined geometry and/or topography such that it promotes generation of a biofilm of a particular thickness.
- Other topographical patterns contemplated by the present invention are described in Graham and Cady, Coatings, 2014, 4, pages 37-59, the contents of which are incorporated herein by reference.
- Exemplary solid surfaces on which the culturing can be carried out include a wide range of substrates, ranging from various polymeric materials (silicone, polystyrene, polyurethane, and epoxy resins) to metals and metal oxides (silicon, titanium, aluminum, silica, and gold). Fabrication techniques (soft lithography and double casting molding techniques, microcontact printing, electron beam lithography, nanoimprint lithography, photolithography, electrodeposition methods, etc.) can be carried out on such materials in order to alter the topography of the solid surface.
- conditions of the co-culture that may be altered include, but are not limited to environmental parameters such as pH, nutrient concentration, the ratio between the beneficial bacteria: biofilm producing bacteria and temperature.
- the co-culturing is carried out in a bioreactor.
- bioreactor refers to an apparatus adapted to support the biofilm of the invention.
- the bioreactor will generally comprise one or more supports for the biofilm which may form a film thereover, and wherein the support is adapted to provide a significant surface area to enhance the formation of the biofilm.
- the bioreactor s of the invention may be adapted for continuous throughput.
- the conditions of the co-culture can be altered by altering the microfluidics (e.g. sheer stress) of the system.
- the agents or conditions are selected that bring about an advantageous change in a property of the biofilm.
- the property is an amount of biofilm.
- the property is a thickness of biofilm.
- the property is a density of the biofilm.
- the property is the rate in which the biofilm is formed.
- the property is the amount of beneficial bacteria which is incorporated into the biofilm.
- the property is the resistance to temperature and/or pH.
- the property is the amount of beneficial bacteria released from the biofilm over a period of time. This may be of particular relevance when a controlled release of the beneficial bacteria is required. For example, it may be advantageous to incorporate bacteria which are beneficial for the skin, scalp or dental applications in biofilms of which the rate of release of the beneficial bacteria therefrom is selected for maximum therapeutic effect.
- the present inventors have now found that altering the pH of the growth substrate to higher than 6, encourages bacteria that utilize the KinD-SpoOA pathway (e.g. being of the genus Bacillus, such as of the species B. subtilis) to be incorporated into a biofilm when cultured in MRS.
- the KinD-SpoOA pathway e.g. being of the genus Bacillus, such as of the species B. subtilis
- the co-culturing of the beneficial bacteria being of the genus lactobacillus (e.g. the species L. plantarum) and the biofilm-producing bacteria being of the genus Bacillus (e.g. of the species B. subtilis), carried out in, or on LBGM, milk or MRS (and more specifically MRS) is effected at a pH of between 6.5 and 9; 6.5-and 8; 6.5 and 7.5; 6.8 and 9; 6.8 and 8; 6.8 and 7.5.
- the biofilm producing bacteria is not B. subtilis MS 1577 or 3610.
- the co-culturing of this aspect of the present invention may be carried out in the presence of additional agents that serve to increase propagation of the bacteria and/or enhance biofilm formation.
- agents include for example acetoin.
- the amount of acetoin and the timing of addition may be altered so as to promote optimal biofilm production. In one embodiment, about 0.01 - 5 % acetoin is used. In another embodiment, about 0.01 - 4 % acetoin is used. In another embodiment, about 0.01 - 3 % acetoin is used. In another embodiment, about 0.01 - 2 % acetoin is used. In another embodiment, about 0.01 - 1 % acetoin is used. In another embodiment, about 0.01 - 0.5 % acetoin is used.
- the present inventors contemplate a culture comprising acetoin, a biofilm comprising a bacillus bacteria and a culture medium.
- the culture medium is one which is mentioned in Table 1 (for example LB).
- about 0.05 - 5 % acetoin is used. In another embodiment, about 0.05 - 4 % acetoin is used. In another embodiment, about 0.05 - 3 % acetoin is used. In another embodiment, about 0.05 - 2 % acetoin is used. In another embodiment, about 0.05 - 1 % acetoin is used. In another embodiment, about 0.05 - 0.5 % acetoin is used.
- 0.1 - 5 % acetoin is used. In another embodiment, about 0.1 - 4 % acetoin is used. In another embodiment, about 0.1 - 3 % acetoin is used. In another embodiment, about 0.1 - 2 % acetoin is used. In another embodiment, about 0.1 - 1 % acetoin is used. In another embodiment, about 0.1 - 0.5 % acetoin is used.
- the co-cultures of this aspect of the present invention are propagated for a length of time sufficient to generate a biofilm which incorporates both the beneficial bacteria and the biofilm generating bacteria.
- the co-cultures are grown to maximal plateau growth phase of the beneficial bacteria, at which time they may be harvested for maximal biofilm production.
- the co-cultures are grown to maximal plateau growth phase of the biofilm-producing bacteria, at which time they may be harvested for maximal biofilm production.
- the bacteria may be cultured for at least 3 hours, at least 6 hours, at least 12 hours, at least 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days or 7 days or longer. In one embodiment, the bacteria are not cultured for longer than 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks or 6 weeks.
- the biofilm is harvested (i.e. removed from the growth substrate).
- the biofilm (and/or bacteria incorporated therein) may be subject to drying (i.e. dehydrating), freezing, spray drying, or freeze-drying.
- drying i.e. dehydrating
- freezing i.e. freezing
- spray drying i.e. freezing
- freeze-drying i.e. freezing
- the biofilm is treated in a way that preserves the viability of the bacteria.
- the biofilm-producing bacteria is present in the bacterial composition in an amount of from 10 3 to 1015 colony forming units per gram of the bacterial composition (e.g. probiotic composition).
- the amount (in weight) of non-cellular material (e.g. exopolysaccharides and/or amyloid fibers) in the composition may be higher than the amount (in weight) of cellular material (e.g. bacterial cells).
- the weight of non-cellular material (e.g. exopolysaccharides and/or amyloid fibers) in the composition may be at least 5 %, 10 %, 20 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 %, 90 % or 100 % higher than the weight of cellular material (e.g. bacterial cells) in the composition.
- the amount (in weight) of non-cellular material (e.g. exopolysaccharides and/or amyloid fibers) in the composition may be lower than the amount (in weight) of cellular material (e.g. bacterial cells).
- the weight of cellular material (e.g. bacterial cells) in the composition may be at least 5 %, 10 %, 20 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 %, 90 % or 100 % higher than the weight of non-cellular material (e.g. e.. exopolysaccharides and/or amyloid fiber) in the composition.
- the weight ratio of non-cellular material (e.g. exopolysaccharides): bacterial cells in the compositions described herein may be between 99:1 - 1:99. In some embodiments the weight ratio of non-cellular material (e.g. exopolysaccharides): bacterial cells in the compositions described herein may be between 99: 1 - 50:50. In some embodiments the weight ratio of non- cellular material (e.g. exopolysaccharides): bacterial cells in the compositions described herein may be between 99: 1 - 70:30.
- the bacterial composition is a probiotic composition.
- the probiotic composition comprises from about 10 3 to 1015 colony forming units ("CFUs") of the biofilm-producing microorganism per gram of finished product. In some embodiments, the probiotic composition comprises from about 10 4 to about 10 14 CFUs of the biofilm-producing microorganism per gram of finished product. In some embodiments, the probiotic composition comprise from about 10 5 to about 10 15 CFUs of biofilm- producing microorganism per gram of finished product. In some embodiments, the probiotic composition comprises from about 10 6 to 10 11 colony forming units of the biofilm-producing microorganism per gram of finished product. In some embodiments, the probiotic composition comprises from about 10 2 to about 105 colony forming units of the biofilm-producing microorganism per gram of finished product.
- CFUs colony forming units
- At least 20 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 %, 90% or more of the beneficial bacteria of the composition are viable (i.e. propagate). Furthermore, at least 20 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 %, 90% or more of the biofilm-producing bacteria of the composition are viable (i.e. propagate).
- the bacterial composition is a probiotic composition.
- Exemplary beneficial bacteria that may be present in the probiotic composition are those that belong to the genus lactobacillus (as described herein above).
- the probiotic composition may comprise additional beneficial bacteria such as those belonging to the Bifidobacterium genus.
- Contemplated species of Bifidobacterium that may be present in the probiotic composition of this aspect of the present invention include, but are not limited to Bifidobacterium longum, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium adolecentis, Bifidobacterium lactis, and Bifidobacterium animalis.
- the probiotic composition comprises a species that belongs to the genus lactobacillus e.g.
- the bacterial compositions disclosed herein are in any form suitable for administering the composition to a mammalian subject.
- the composition is in the form of a tablet, a powder or a liquid. If provided as a powder, combining the powder with a suitable liquid (e.g., liquid dairy product, fruit or vegetable juice, blended fruit or vegetable juice product, etc.) is specifically contemplated.
- a suitable liquid e.g., liquid dairy product, fruit or vegetable juice, blended fruit or vegetable juice product, etc.
- the bacterial compositions disclosed herein are administered to a subject prior to, concomitant with or following administration of an antibiotic agent.
- the conditions of the co-culture may be such that the biofilm which is generated releases the beneficial bacteria in the body such that they are not subject to the activity of the antibiotic agent.
- the bacterial compositions described herein are formulated for topical administration - e.g. in a cream, a gel, a lotion, a shampoo, a rinse.
- the bacterial compositions may be administered to the skin or the scalp.
- the bacterial compositions may be useful for dental applications. For such applications they may be administered to the gums.
- compositions described herein are incorporated into a food product.
- food product refers to any substance containing nutrients that can be ingested by an organism to produce energy, promote health and wellness, stimulate growth, and maintain life.
- enriched food product refers to a food product that has been modified to include the composition comprising composition described herein, which provides a benefit such as a health/wellness-promoting and/or disease- preventing/mitigating/treating property beyond the basic function of supplying nutrients.
- the probiotic composition can be incorporated into any food product.
- Exemplary food products include, but are not limited to, protein powder (meal shakes), baked goods (cakes, cookies, crackers, breads, scones and muffins), dairy-type products (including but not limited to cheese, yogurt, custards, rice pudding, mousses, ice cream, frozen yogurt, frozen custard), desserts (including, but not limited to, sherbet, sorbet, water-ices, granitas and frozen fruit purees), spreads/margarines, pasta products and other cereal products, meal replacement products, nutrition bars, trail mix, granola, beverages (including, but not limited to, smoothies, water or dairy beverages and soy-based beverages), and breakfast type cereal products such as oatmeal.
- protein powder meal shakes
- baked goods cakes, cookies, crackers, breads, scones and muffins
- dairy-type products including but not limited to cheese, yogurt, custards, rice pudding, mousses, ice cream, frozen yogurt, frozen
- the probiotic composition described herein may be in solution, suspended, emulsified or present as a solid.
- the enriched food product is a meal replacement product.
- the term "meal replacement product” as used herein refers to an enriched food product that is intended to be eaten in place of a normal meal.
- Nutrition bars and beverages that are intended to constitute a meal replacement are types of meal replacement products.
- the term also includes products which are eaten as part of a meal replacement weight loss or weight control plan, for example snack products which are not intended to replace a whole meal by themselves, but which may be used with other such products to replace a meal or which are otherwise intended to be used in the plan. These latter products typically have a calorie content in the range of from 50-500 kilocalories per serving.
- the food product is a dietary supplement.
- dietary supplement refers to a substance taken by mouth that contains a "dietary ingredient” intended to supplement the diet.
- dietary ingredients includes, but is not limited to, the composition comprising the probiotic composition as described herein as well as vitamins, minerals, herbs or other botanicals, amino acids, and substances such as enzymes, organ tissues, glandulars, and metabolites.
- the food product is a medical food.
- medical food as used herein means a food which is formulated to be consumed or administered entirely under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation.
- probiotic microorganisms can improve animal efficiency and health.
- Specific examples include increased weight gain-to- feed intake ratio (feed efficiency), improved average daily weight gain, improved milk yield, and improved milk composition by dairy cows as described by U.S. Pat. Nos. 5,529,793 and 5,534,271.
- the administration of probiotic organisms can also reduce the incidence of pathogenic organisms in cattle, as reported by U.S. Pat. No. 7,063,836.
- the probiotic composition described herein can be incorporated into an animal feed.
- the probiotic composition is designed for continual or periodic administration to ruminal, cecal or intestinal fermentors throughout the feeding period in order to reduce the incidence and severity of diarrhea and/or overall health.
- the probiotic composition can be introduced into the rumen, cecum and/or intestines of the animal.
- the probiotic composition described herein are incorporated into a pharmaceutical product or composition.
- Pharmaceutical compositions comprise a prophylactically or therapeutically effective amount of the composition described herein and typically one or more pharmaceutically acceptable carriers or excipients (which are discussed below).
- compositions described herein that are, in some embodiments, powdered, tableted, encapsulated or otherwise formulated for oral administration.
- the compositions may be provided as pharmaceutical compositions, nutraceutical compositions (e.g., a dietary supplement), or as a food or beverage additive, as defined by the U.S. Food and Drug Administration.
- nutraceutical compositions e.g., a dietary supplement
- food or beverage additive as defined by the U.S. Food and Drug Administration.
- the dosage form for the above compositions are not particularly restricted. For example, liquid solutions, suspensions, emulsions, tablets, pills, capsules, sustained release formulations, powders, suppositories, liposomes, microparticles, microcapsules, sterile isotonic aqueous buffer solutions, and the like are all contemplated as suitable dosage forms.
- compositions typically include one or more suitable diluents, fillers, salts, disintegrants, binders, lubricants, glidants, wetting agents, controlled release matrices, colorings, flavoring, carriers, excipients, buffers, stabilizers, solubilizers, commercial adjuvants, and/or other additives known in the art.
- any pharmaceutically acceptable (i.e., sterile and acceptably non-toxic as known in the art) liquid, semisolid, or solid diluent that serves as a pharmaceutical vehicle, excipient, or medium can be used.
- exemplary diluents include, but are not limited to, polyoxyethylene sorbitan monolaurate, magnesium stearate, calcium phosphate, mineral oil, cocoa butter, and oil of theobroma, methyl- and propylhydroxybenzoate, talc, alginates, carbohydrates, especially mannitol, .alpha.-lactose, anhydrous lactose, cellulose, sucrose, dextrose, sorbitol, modified dextrans, gum acacia, and starch.
- Pharmaceutically acceptable fillers can include, for example, lactose, microcrystalline cellulose, dicalcium phosphate, tricalcium phosphate, calcium sulfate, dextrose, mannitol, and/or sucrose. Salts, including calcium triphosphate, magnesium carbonate, and sodium chloride, may also be used as fillers in the pharmaceutical compositions.
- Binders may be used to hold the composition together to form a hard tablet.
- exemplary binders include materials from organic products such as acacia, tragacanth, starch and gelatin.
- Other suitable binders include methyl cellulose (MC), ethyl cellulose (EC) and carboxymethyl cellulose (CMC).
- an enriched food product further comprises a bioavailability enhancer, which acts to increase the absorption of the sorbable natural product(s) by the body.
- Bioavailability enhancers can be natural or synthetic compounds.
- the enriched food product comprising the composition described herein further comprises one or more bioavailability enhancers in order to enhance the bioavailability of the bioactive natural product(s).
- Natural bioavailability enhancers include ginger, caraway extracts, pepper extracts and chitosan.
- the active compounds in ginger include 6-gingerol and 6-shogoal.
- Caraway oil can also be used as a bioavailability enhancer (U.S. Patent Application 2003/022838).
- Piperine is a compound derived from pepper (Piper nigrum or Piper longum) that acts as a bioavailability enhancer (see U.S. Pat. No. 5,744,161). Piperine is available commercially under the brand name Bioperine R TM (Sabinsa Corp., Piscataway, N.J.).
- the natural bioavailability enhancers is present in an amount of from about 0.02% to about 0.6% by weight based on the total weight of enriched food product.
- suitable synthetic bioavailability enhancers include, but are not limited to surfactants including those composed of PEG-esters such as are commercially available under the tradenames: Gelucire R TM, Labrafil R TM, Labrasol R TM, Lauroglycol R TM, Pleural 01eique R TM (Gattefosse Corp., Paramus, N.J.) and Capmul R TM (Abitec Corp., Columbus, Ohio).
- the amount and administration regimen of the composition is based on various factors relevant to the purpose of administration, for example human or animal age, sex, body weight, hormone levels, or other nutritional need of the human or animal.
- the composition is administered to a mammalian subject in an amount from about 0.001 mg/kg body weight to about 1 g/kg body weight.
- a typical regimen may comprise multiple doses of the composition.
- the composition is administered once per day.
- the composition may be administered to an individual at any time.
- the composition is administered concurrently, or prior to or at the consumption of a meal.
- the bacterial compositions of this aspect of the present invention are formulated for use as an agricultural product.
- the bacterial compositions may be added to an agricultural carrier such as soil or plant growth medium.
- an agricultural carrier such as soil or plant growth medium.
- Other agricultural carriers that may be used include fertilizers, plant-based oils, humectants, or combinations thereof.
- the agricultural carrier may be a solid, such as diatomaceous earth, loam, silica, alginate, clay, bentonite, vermiculite, seed cases, other plant and animal products, or combinations, including granules, pellets, or suspensions.
- Mixtures of any of the aforementioned ingredients are also contemplated as carriers, such as but not limited to, pesta (flour and kaolin clay), agar or flour- based pellets in loam, sand, or clay, etc.
- Formulations may include food sources for the cultured organisms, such as barley, rice, or other biological materials such as seed, leaf, root, plant elements, sugar cane bagasse, hulls or stalks from grain processing, ground plant material or wood from building site refuse, sawdust or small fibers from recycling of paper, fabric, or wood.
- Other suitable formulations will be known to those skilled in the art.
- the agricultural formulation comprises a fertilizer.
- the fertilizer is one that does not reduce the viability of the bacterial composition by more than 20 %, 30 %, 40 %, 50 % or more.
- the agricultural formulation it is advantageous for the agricultural formulation to contain agents such as herbicide, a nematicide, an insecticide, a plant growth regulator, a rodenticide, and a nutrient.
- agents such as herbicide, a nematicide, an insecticide, a plant growth regulator, a rodenticide, and a nutrient.
- Such agents are ideally compatible with the plant onto which the formulation is applied (e.g., it should not be deleterious to the growth or health of the plant).
- the agent is ideally one which does not cause safety concerns for human, animal or industrial use (e.g., no safety issues, or the compound is sufficiently labile that the commodity plant product derived from the plant contains negligible amounts of the compound).
- the agricultural formulations comprising the biofilm of the present invention typically contains between about 0.1 to 95% by weight, for example, between about 1% and 90%, between about 3% and 75%, between about 5% and 60%, between about 10% and 50% in wet weight of the biofilm-incorporated beneficial bacterial population of the present invention.
- the formulation contains at least about 10 CFU or spores per ml of formulation, at least about 10 3 CFU or spores per ml of formulation, at least about 10 4 CFU or spores per ml of formulation, at least about 10 5 CFU or spores per ml of formulation, at least about 10 6 CFU or spores per ml of formulation, or at least about 10 CFU or spores per ml of formulation.
- the presently disclosed agricultural composition may be comprised in an article of manufacture which further comprises an agent which promotes the growth of plants.
- the agents may be formulated together with the biofilm in a single composition, or alternatively packaged separately, but in a single container.
- Suitable agents are described herein above.
- Other suitable agents include fertilizers, pesticides (an herbicide, a nematocide, a fungicide and/or an insecticide), a plant growth regulator, a rodenticide, and a nutrient, as further described herein below.
- the agent which promotes the growth of the plant lacks antibacterial activity.
- compositions, method or structure may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.
- a compound or “at least one compound” may include a plurality of compounds, including mixtures thereof.
- range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
- method refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.
- treating includes abrogating, substantially inhibiting, slowing or reversing the progression of a condition, substantially ameliorating clinical or aesthetical symptoms of a condition or substantially preventing the appearance of clinical or aesthetical symptoms of a condition.
- the probiotic bacterial strain used in this study was Lactobacillus plantarum. This strain routinely is grown in either MRS (Man, Rogosa & Sharpe) broth or MRS broth solidified using 1.5% agar (DifcoTM).
- MRS Man, Rogosa & Sharpe
- MRS broth solidified using 1.5% agar DifcoTM.
- the Bacillus subtilis wild strain NCIB3610 and its derivatives are typically cultured in LB (10 g of tryptone, 5 g of yeast extract, 5 g of NaCl per liter) broth or LB solidified with 1.5% agar. Prior to their use, L. plantarum and B. subtilis were grown on a hard agar plate for 48 h or overnight, respectively, both at 37 Q C. A starter culture of each strain was prepared using a single bacterial colony, L.
- MRS medium at pH 7 was used since it was found to be effective in promoting biofilm formation by B. subtilis and suitable for co-culture cultivation of B. subtilis and probiotic lactic acid bacteria (LAB).
- B. subtilis cells were mixed with an equal amount of L. plantarum cells to a final concentration of 10 cells/mL of each strain, and then diluted 1: 100 into MRS pH 7. The cells in mixed cultures were incubated aerobically at 37°C at 50 rpm for 7-8 h.
- Assay for colony and pellicle biofilm formation For colony architecture analysis, 3 ⁇ )L of starter cultures were spotted onto MRS agar plates or control LB and incubated at 30 °C for 72 h. For pellicle formation analysis, the starter cultures were diluted 1: 100 into 3.5 mL MRS broth or control LB in a 12-well plates and incubated without agitation at 30 °C for 48 h. Images were taken using a Zeiss Stemi 2000-C microscope with an axiocam ERc 5s camera (Zeiss, Germany).
- ⁇ -galactosidase assay Cells were harvested from colonies grown in either LB, LB supplemented with MRS in different ratio (1: 1, 1:5, and 5:1) or MRS with pH adjustment to 7 on solid medium at 30 °C and resuspended in phosphate -buffered saline (PBS) solution. Typical long bundled chains of cells in the biofilm colony were disrupted using mild sonication. The optical density (OD) of the cell samples were normalized to an OD 6 oo of 1.0 in PBS. One milliliter of bacterial cell suspensions were collected and assayed according to standard procedure.
- PBS phosphate -buffered saline
- L. plantarum cells were grown in co-culture as described above with B. subtilis (YC161) aborting GFP or B. subtilis (YC189) aborting CFP in modified MRS broth.
- Cell suspensions of each bacterium grown as monospecies culture served as control samples.
- One milliliter of each culture was collected and centrifuged at 5000 rpm for 2 minutes. After removing supernatant, the cells were washed with 1 mL of PBS buffer and then following centrifugation (at 5000 rpm for 2 minutes) resuspended in 100 ⁇ of the same buffer. 5 ⁇ from each sample were placed on a microscopy glass slide and visualized in a transmitted light microscope using Nomarski differential interference contrast (DIC).
- DIC Nomarski differential interference contrast
- SEM Scanning electron microscopy
- SIF simulated intestinal fluid
- pancreatic enzymes were added to the digestion mixture to achieve following activities in the final mixture: porcine trypsin (SIGMA T0303) (100 U mL “1 ), bovin chymotrypsin (SIGMA C4129) (25 U mL “ l ), porcine pancreatic a amylase (SIGMA A3176) (200 U mL “1 ), porcine pancreatic lipase (SIGAM L3126) (2000 U mL "1 ).
- bile salts SIGMA T4009 were added to give a final concentration of 10 mM in the final mixture and then the samples were incubated again for 2.5 h.
- One milliliter from each sample collected after gastric and intestinal phases and the numbers of viable L. plantarum cells were determined using CFU counting method as described above.
- biofilms have an increased tolerance toward various unfavorable environmental conditions, apparently due to production of extracellular matrix (Friedman, Kolter, & Branda, 2005).
- the present inventors thus hypothesized that extracellular matrix produced by robust biofilm former bacterium B. subtilis may provide increased protection to other species such as probiotic bacteria during their growth in co-culture biofilm system.
- a specialized medium was developed where L. plantarum and B. subtilis are able to grow in co-culture. It was found that by modifying the pH of the MRS to pH 7, it was possible to grow these bacteria in co-culture. As shown in Figure 13, the co-culture cultivation had no effect on L. plantarum and B.
- subtilis growth (compared to their growth in pure culture), indicating that there are no antagonistic interactions between these bacteria at given conditions.
- modification of MRS medium promotes strong biofilm formation by B. subtilis ( Figure 2). Since B. subtilis appears to be sensitive to acidic pH, the pH of MRS medium used for co-culture cultivation was gradually elevated in order to find a pH value suitable for Bacillus growth. The increase of pH from 6 to 8 led to a proportional increase in robustness of biofilm phenotype of both colony and pellicle biofilm ( Figure 2). When the pH was adjusted to 6 weak growth on solid MRS medium was seen and no growth in liquid medium.
- LB medium that is usually used to culture B. subtilis
- MRS MRS 1: 1, 1:5, and 5: 1).
- Figure 3 The effect of increasing MRS concentration on matrix gene expression in B. subtilis using tapA and eps operons was also investigated, since their products are major components of extracellular matrix. It was found that the expression of tap A increased proportionally with the concentration of MRS in LB ( Figures 4A-B). The expression of eps increased proportionally to the concentration of MRS up to 80% MRS, than a decrease of expression for 100% was detected ( Figures 5A-B).
- the present inventors determined whether MRS triggers biofilm formation through the Kin-SpoOA pathway previously described for B. subtilis (Shemesh and Chai, 2013 Journal of Bacteriology, 2013, Vol 195, No.12 pages 2747-2754). They tested different B. subtilis mutants for biofilm formation (AkinA, AkinB, AkinC, AkinD, AkinE, AkinAB, AkinCD, AspoOA, AepsAtasA) or overproducing biofilm (AabrB). Firstly, they determined biofilm phenotype of mutants deficient in histidine kinases responsible for sensing environmental signals that induce biofilm formation.
- the modified MRS medium was used to investigate dual species biofilm by co-culturing fluorescently tagged B. subtilis cells, which constitutively express GFP (YC161), together with L. plantarum cells. Generated biofilm was visualized using CLSM. As can be seen in Figure 8A (top panel), the generated biofilm consisted of both fluorescent and non-fluorescent cells. L. plantarum cells were surrounded by B. subtilis cells which attached to each other to form a biofilm-related structure (bundle). This is further illustrated in Figure 8B which illustrates the co-cultured biofilm of B. subtilis and L. plantarum in LBGM medium.
- biofilm formation in B. subtilis depends on the synthesis of extracellular matrix
- the present inventors sought to determine whether the production of extracellular matrix takes place during dual species biofilm development.
- the level of the matrix gene expression in the formed biofilm was analyzed using transcriptional fusion of the promoter for tapA-sipW-tasA (operon responsible for synthesis of protein components of biofilm matrix in B. subtilis) to the cfp gene encoding cyan fluorescent protein (YC189), as described previously (Shemesh, Kolter, & Losick, 2010, J Bacteriol 192, 6352-6356) (P tap A-cfp).
- subtilis cells grown as monoculture form also biofilm characterized with homogenous structure in which long filaments of the cells are bound together by an extracellular matrix (Figure 9A).
- the L. plantarum cells could not form notable biofilm in monospecies culture. The observations described above indicate that the extracellular matrix produced by B. subtilis cells could be shared with L. plantarum cells and thus provide them with possible protection against environmental stresses.
- the dual species biofilm facilitates survival ofL. plantarum in hostile environments
- L. plantarum cells grown in co-culture biofilm were exposed to heating at 63 °C for 1 and 3 min.
- L. plantarum cells that grew in monospecies culture were used as control. Following 1 and 3 min of heat treatment, L.
- L. plantarum and B. subtilis mutant strains either deficient in biofilm formation (AepsAtasA) or an overproducing biofilm matrix (AabrB)
- the co-cultures were subjected to heat treatment pasteurization.
- L. plantarum cells grown in mono-species culture and in co-culture with wild type B. subtilis were used as control.
- Figure 11 A L. plantarum cells grown with the cells of AepsAtasA double mutant did not show a significant difference in their survival level compare to L. plantarum grown in mono-species culture.
- Acetoin enhances biofilm formation
- Food products are often enriched by different food additives which may improve organoleptic and sensory characteristics of the products.
- additives there are important small molecules such as acetoin which can improve the flavor of different food products.
- Acetoin is a neutral molecule which widely exists in nature. Some microorganisms, higher plants, insects, and higher animals have the ability to synthesize acetoin.
- Those additives can affect the physiology of many bacteria associated with human health, and affect development of multicellular community of bacterial cells known as a biofilm. Biofilm formation depends on the synthesis of an extracellular matrix that holds the constituent cells together.
- the matrix In Bacillus subtilis, a prebiotic bacteria, the matrix has two main components, an exopolysaccharide synthesized by the products of the epsA-0 operon, and amyloid fibers encoded by tapA-sipW-tasA operon.
- acetoin triggers the biofilm bundles formation in Bacillus subtilis. In the absence of acetoin, no biofilm formation is observed when grown in LB medium ( Figure 15A).
- Figures 16A-B illustrate that acetoin triggers a colony type biofilm formation in Bacillus subtilis. Transcription of the tap A operon responsible for the matrix production in B. subtilis was shown to be highly upregulated by acetoin ( Figures 17A-D).
- the cells express high levels of the extracellular matrix components, in response to acetoin, which are crucial for biofilm formation.
- the objective of this experiment was to test the ability of NCIB3610 (isolated from soil) and 127185/2 (isolated from dairy environment) to protect L. plantarum against hostile environmental conditions during growth in co-culture system.
- the growth medium selected for the co-culture system of B. subtilis and L. plantarum was modified (pH adjusted) MRS medium.
- Characterization of biofilm formation was performed using a stereoscopic microscope or confocal laser scanning microscope (for colony or bundles type biofilm, respectively).
- Figures 18A-B are photographs depicting the biofilm generated from the B. subtilis strains NCIB3610 and 127185/2 respectively.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IL2017/050603 WO2017208237A1 (en) | 2016-05-29 | 2017-05-29 | Method of generating bacterial compositions |
US201762588365P | 2017-11-19 | 2017-11-19 | |
US201862644528P | 2018-03-18 | 2018-03-18 | |
PCT/IL2018/050588 WO2018220630A1 (en) | 2017-05-29 | 2018-05-29 | Method of generation bacterial compositions comprising a biofilm with benefecial bacteria |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3630944A1 true EP3630944A1 (en) | 2020-04-08 |
EP3630944A4 EP3630944A4 (en) | 2021-03-31 |
Family
ID=64455982
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18810460.8A Withdrawn EP3630944A4 (en) | 2017-05-29 | 2018-05-29 | Method of generation bacterial compositions comprising a biofilm with benefecial bacteria |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP3630944A4 (en) |
JP (1) | JP7228533B2 (en) |
CN (1) | CN110945116A (en) |
CA (1) | CA3064942A1 (en) |
IL (1) | IL271044A (en) |
WO (1) | WO2018220630A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017208237A1 (en) | 2016-05-29 | 2017-12-07 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Method of generating bacterial compositions |
EP3946608A4 (en) * | 2019-03-25 | 2022-12-28 | The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Institute) | Method of treating bovine mastitis |
AR119025A1 (en) * | 2019-05-29 | 2021-11-17 | Chr Hansen As | COMPOSITION COMPRISING A BIOFILM-FORMING BACILLUS |
CN111254089B (en) * | 2019-12-30 | 2022-01-18 | 杭州娃哈哈科技有限公司 | Lactobacillus plantarum with weight losing function and application thereof |
CN112869171A (en) * | 2021-01-29 | 2021-06-01 | 陕西科技大学 | Probiotic dietary fiber powder and preparation method thereof |
CN113083383B (en) * | 2021-03-18 | 2022-10-25 | 华中农业大学 | Microfluidic chip device, preparation method and soil microbial community culture method |
CN116555069B (en) * | 2022-12-27 | 2023-10-20 | 华北电力大学 | Alkana diesel oil bacterium with salt-tolerant aerobic denitrification characteristic |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009017124A1 (en) * | 2007-07-31 | 2009-02-05 | Nihon University | Method for production of biofilm |
JP2010195711A (en) * | 2009-02-25 | 2010-09-09 | Kao Corp | Biofilm formation promoter |
CN103911323B (en) * | 2014-03-28 | 2016-06-29 | 内蒙古和美科盛生物技术有限公司 | Bacillus licheniformis, bacillus subtilis and lactobacillus plantarum preparation and preparation |
US20170020178A1 (en) * | 2015-03-25 | 2017-01-26 | Functional Fungi, Llc | Nutritionally and Botanically Enhanced Microbial/Bacterial Biomass |
WO2016181228A2 (en) * | 2015-05-11 | 2016-11-17 | Mybiotix Pharma Ltd. | Systems and methods for growing a biofilm of probiotic bacteria on solid particles for colonization of bacteria in the gut |
ITUA20163807A1 (en) * | 2016-05-25 | 2017-11-25 | Univ Degli Studi Di Foggia | METHOD FOR THE PRODUCTION OF PROBIOTIC MICROBIAL BIOFILMS AND RELATED USES |
WO2017208237A1 (en) * | 2016-05-29 | 2017-12-07 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Method of generating bacterial compositions |
-
2018
- 2018-05-29 EP EP18810460.8A patent/EP3630944A4/en not_active Withdrawn
- 2018-05-29 CN CN201880048611.XA patent/CN110945116A/en active Pending
- 2018-05-29 JP JP2019565540A patent/JP7228533B2/en active Active
- 2018-05-29 CA CA3064942A patent/CA3064942A1/en active Pending
- 2018-05-29 WO PCT/IL2018/050588 patent/WO2018220630A1/en active Application Filing
-
2019
- 2019-11-28 IL IL271044A patent/IL271044A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP7228533B2 (en) | 2023-02-24 |
JP2020528264A (en) | 2020-09-24 |
EP3630944A4 (en) | 2021-03-31 |
IL271044A (en) | 2020-01-30 |
WO2018220630A1 (en) | 2018-12-06 |
CA3064942A1 (en) | 2018-12-06 |
CN110945116A (en) | 2020-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11297868B2 (en) | Method of generating bacterial compositions | |
US11225641B2 (en) | Probiotic Bifidobacterium strain | |
JP7228533B2 (en) | Method for Producing Bacterial Compositions Comprising Biofilms with Beneficial Bacteria | |
AU751284B2 (en) | Strain of bacteria of the species lactobacillus paracasei subsp. paracasei, composition thereof for use in food and product containing said strain | |
US20060121015A1 (en) | Probiotic bifidobacterium strains | |
US20030091549A1 (en) | Probiotic lactobacillus salivarius strains | |
CN100455203C (en) | A probiotic composition comprising at least two lactic acid bacterial strains which are able to colonise the gastrointestinal tracts in combination with having intestinal survival property, intestinal | |
US20200190463A1 (en) | Method of generation bacterial compositions comprising a biofilm with benefecial bacteria | |
EP3092320A1 (en) | New strains of the genus lactobacillus and use thereof | |
CN101432006B (en) | Method and use of lactic acid bacteria with increased acid tolerance | |
US20020081311A1 (en) | Probiatic product | |
Maisonneuve et al. | Comparison of yoghurt, heat treated yoghurt, milk and lactose effects on plasmid dissemination in gnotobiotic mice | |
Kotikalapudi et al. | In vitro characterization of probiotic survival, adherence and antimicrobial resistance: Candidate selection for encapsulation in a pea protein isolate-alginate delivery system | |
Naidu et al. | Identification and characterization of Bacillus sp. for probiotic properties isolated from human faeces | |
Narakaew et al. | Preliminary characterization of Lactobacillus salivarius K7 for probiotic properties | |
Mathipa | Pre-adaptation of selected probiotic strains to multiple stress factors: consequent effect on their stability and probiotic properties | |
ZA200400555B (en) | Probiotic bifidobacterium strains. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20191217 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: C12N0001200000 Ipc: C12N0001040000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20210301 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 1/20 20060101ALI20210223BHEP Ipc: C12R 1/25 20060101ALI20210223BHEP Ipc: A61K 35/742 20150101ALI20210223BHEP Ipc: C12N 1/38 20060101ALI20210223BHEP Ipc: A61K 35/744 20150101ALI20210223BHEP Ipc: A61P 3/02 20060101ALI20210223BHEP Ipc: C12N 1/04 20060101AFI20210223BHEP Ipc: A61K 45/06 20060101ALI20210223BHEP Ipc: A61K 35/747 20150101ALI20210223BHEP Ipc: C12R 1/125 20060101ALI20210223BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20231201 |